NOTCH2 and neoplasm: Tarextumab (OMP‐59R5) is a fully human IgG2 antibody against the Notch2 and Notch3 receptors.12 Preclinical studies using pancreatic xenograft models have found that treatment with the combination of tarextumab, gemcitabine, and nab‐paclitaxel induced tumor regression, decreased CSC frequency, and delayed tumor progression compared to treatment with cytotoxic therapy alone.12 Tarextumab also downregulated Rg5, a marker of developing pericytes, and facilitated pericyte recruitment to endothelial cells.